Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc reported a series of small share acquisitions by senior executives under the company’s Share Reward Plan. On 9 December 2025, Chief Executive Officer Emma Walmsley, Chief Financial Officer Julie Brown and several other senior leaders, including the group general counsel, heads of global communications, corporate development, global supply chain, global affairs, ViiV Healthcare and the company secretary, each acquired GSK ordinary shares of 31¼ pence. The purchases combined partnership and matching shares, with individual totals ranging from 12 to 14 ordinary shares at a price of £18.0780 per share. All transactions took place on the London Stock Exchange (XLON) and are routine disclosures of dealings by persons discharging managerial responsibilities.
GSK plc reported a series of small share acquisitions by senior executives under the company’s Share Reward Plan. On 9 December 2025, Chief Executive Officer Emma Walmsley, Chief Financial Officer Julie Brown and several other senior leaders, including the group general counsel, heads of global communications, corporate development, global supply chain, global affairs, ViiV Healthcare and the company secretary, each acquired GSK ordinary shares of 31¼ pence. The purchases combined partnership and matching shares, with individual totals ranging from 12 to 14 ordinary shares at a price of £18.0780 per share. All transactions took place on the London Stock Exchange (XLON) and are routine disclosures of dealings by persons discharging managerial responsibilities.
GSK plc has applied to list 250,000 new Ordinary Shares of 31¼p each on the Financial Conduct Authority’s Official List and to trade them on the London Stock Exchange. These shares are being reserved under a block listing for the GlaxoSmithKline plc Share Save Plan 2022, a plan that allows eligible employees to acquire shares in the company.
Admission of these shares is expected to become effective on 12 December 2025. Once issued, the new shares will rank equally with all existing GSK Ordinary Shares, meaning they will carry the same rights to dividends and voting as the current share capital.
GSK plc has applied to list 250,000 new Ordinary Shares of 31¼p each on the Financial Conduct Authority’s Official List and to trade them on the London Stock Exchange. These shares are being reserved under a block listing for the GlaxoSmithKline plc Share Save Plan 2022, a plan that allows eligible employees to acquire shares in the company.
Admission of these shares is expected to become effective on 12 December 2025. Once issued, the new shares will rank equally with all existing GSK Ordinary Shares, meaning they will carry the same rights to dividends and voting as the current share capital.
GSK plc reports that on 10 December 2025 it repurchased 220,000 ordinary shares of 31¼ pence each under its existing share buyback programme, acting through BNP Paribas SA. The shares were bought at prices between 1,771.00p and 1,807.00p per share, with a volume-weighted average price of 1,789.73p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, GSK has bought a total of 12,944,733 ordinary shares under this programme. After this transaction, GSK holds 238,409,577 shares in treasury and has 4,077,029,560 ordinary shares in issue, which is also the total number of voting rights in the company. GSK states that treasury shares now represent 5.85% of its voting rights.
GSK plc reports that on 10 December 2025 it repurchased 220,000 ordinary shares of 31¼ pence each under its existing share buyback programme, acting through BNP Paribas SA. The shares were bought at prices between 1,771.00p and 1,807.00p per share, with a volume-weighted average price of 1,789.73p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, GSK has bought a total of 12,944,733 ordinary shares under this programme. After this transaction, GSK holds 238,409,577 shares in treasury and has 4,077,029,560 ordinary shares in issue, which is also the total number of voting rights in the company. GSK states that treasury shares now represent 5.85% of its voting rights.
GSK plc reports that it repurchased 250,000 of its ordinary shares on 9 December 2025 through BNP Paribas SA under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,780.00p and 1,820.00p, at a volume‑weighted average price of 1,800.43p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 12,724,733 ordinary shares under this programme. After the latest transactions, the company holds 238,189,577 shares in treasury and has 4,077,249,560 ordinary shares in issue, which also represents the total number of voting rights. GSK states that, in line with regulatory rules, treasury shares now account for 5.84 per cent of the company’s voting rights, a figure shareholders can use when calculating disclosure thresholds.
GSK plc reports that it repurchased 250,000 of its ordinary shares on 9 December 2025 through BNP Paribas SA under its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,780.00p and 1,820.00p, at a volume‑weighted average price of 1,800.43p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 12,724,733 ordinary shares under this programme. After the latest transactions, the company holds 238,189,577 shares in treasury and has 4,077,249,560 ordinary shares in issue, which also represents the total number of voting rights. GSK states that, in line with regulatory rules, treasury shares now account for 5.84 per cent of the company’s voting rights, a figure shareholders can use when calculating disclosure thresholds.
GSK plc reports that its B7-H3-targeted antibody-drug conjugate GSK'227, now called risvutatug rezetecan, has received Orphan Drug Designation from the US FDA for treating small-cell lung cancer (SCLC). This decision is based on early phase I ARTEMIS-001 data showing durable responses in patients with extensive-stage SCLC, a form of the disease with high relapse rates, few treatment options and a five-year survival rate of about 3%.
This is the fifth major regulatory designation for risvutatug rezetecan, following EMA Orphan Drug Designation in pulmonary neuroendocrine carcinoma, EMA PRIME status in relapsed extensive-stage SCLC, and two US FDA Breakthrough Therapy Designations in relapsed or refractory ES-SCLC and osteosarcoma. GSK has begun a global phase III trial in relapsed extensive-stage SCLC, positioning this investigational therapy as a key part of its oncology pipeline.
GSK plc reports that its B7-H3-targeted antibody-drug conjugate GSK'227, now called risvutatug rezetecan, has received Orphan Drug Designation from the US FDA for treating small-cell lung cancer (SCLC). This decision is based on early phase I ARTEMIS-001 data showing durable responses in patients with extensive-stage SCLC, a form of the disease with high relapse rates, few treatment options and a five-year survival rate of about 3%.
This is the fifth major regulatory designation for risvutatug rezetecan, following EMA Orphan Drug Designation in pulmonary neuroendocrine carcinoma, EMA PRIME status in relapsed extensive-stage SCLC, and two US FDA Breakthrough Therapy Designations in relapsed or refractory ES-SCLC and osteosarcoma. GSK has begun a global phase III trial in relapsed extensive-stage SCLC, positioning this investigational therapy as a key part of its oncology pipeline.
GSK plc reported a share transaction by a senior manager. Sally Jackson, SVP, Global Communications & CEO Office, sold 6,000 ordinary shares of GSK on the London Stock Exchange. The shares were sold at a price of £18.2870 per share on 2025-12-05. This disclosure is a routine notification of dealings by a person discharging managerial responsibilities in GSK’s securities.
GSK plc reported a share transaction by a senior manager. Sally Jackson, SVP, Global Communications & CEO Office, sold 6,000 ordinary shares of GSK on the London Stock Exchange. The shares were sold at a price of £18.2870 per share on 2025-12-05. This disclosure is a routine notification of dealings by a person discharging managerial responsibilities in GSK’s securities.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 229,000 ordinary shares on 8 December 2025 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 1,803.00p and 1,822.00p per share, with a volume‑weighted average price of 1,814.42p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,474,733 ordinary shares. After this latest transaction, it holds 237,939,577 shares in treasury and has 4,077,499,560 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by the treasury shares is 5.84%, a reference figure for investors monitoring notification thresholds under UK disclosure rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 229,000 ordinary shares on 8 December 2025 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 1,803.00p and 1,822.00p per share, with a volume‑weighted average price of 1,814.42p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,474,733 ordinary shares. After this latest transaction, it holds 237,939,577 shares in treasury and has 4,077,499,560 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by the treasury shares is 5.84%, a reference figure for investors monitoring notification thresholds under UK disclosure rules.
GSK plc reports that on 05 December 2025 it repurchased 248,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,798.00p and 1,833.00p per share, with a volume-weighted average price of 1,818.74p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,245,733 ordinary shares. Following this latest purchase, the company holds 237,710,577 shares in treasury and has 4,077,728,560 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.83% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that on 05 December 2025 it repurchased 248,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,798.00p and 1,833.00p per share, with a volume-weighted average price of 1,818.74p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,245,733 ordinary shares. Following this latest purchase, the company holds 237,710,577 shares in treasury and has 4,077,728,560 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.83% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that it repurchased 233,000 of its ordinary shares of 31¼ pence each on 4 December 2025 under its existing share buyback programme, using BNP Paribas SA as broker. The shares were bought at prices between 1,819.00p and 1,852.50p per share, with a volume-weighted average price of 1,832.36p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought 11,997,733 ordinary shares under this programme. After this latest purchase, GSK holds 237,462,577 shares in treasury and has 4,077,971,107 ordinary shares in issue, which is also the total number of voting rights. The company states that, following this transaction, treasury shares represent 5.82% of the voting rights.
GSK plc reports that it repurchased 233,000 of its ordinary shares of 31¼ pence each on 4 December 2025 under its existing share buyback programme, using BNP Paribas SA as broker. The shares were bought at prices between 1,819.00p and 1,852.50p per share, with a volume-weighted average price of 1,832.36p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought 11,997,733 ordinary shares under this programme. After this latest purchase, GSK holds 237,462,577 shares in treasury and has 4,077,971,107 ordinary shares in issue, which is also the total number of voting rights. The company states that, following this transaction, treasury shares represent 5.82% of the voting rights.
GSK plc reports that on 03 December 2025 it repurchased 218,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,830.00p and 1,848.00p, with a volume-weighted average price of 1,839.30p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,764,733 ordinary shares under this programme. After this latest transaction, GSK holds 237,229,577 ordinary shares in treasury and has 4,078,204,107 ordinary shares in issue, giving a total of 4,078,204,107 voting rights. The percentage of voting rights attributable to treasury shares is stated as 5.82 per cent.
GSK plc reports that on 03 December 2025 it repurchased 218,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,830.00p and 1,848.00p, with a volume-weighted average price of 1,839.30p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,764,733 ordinary shares under this programme. After this latest transaction, GSK holds 237,229,577 ordinary shares in treasury and has 4,078,204,107 ordinary shares in issue, giving a total of 4,078,204,107 voting rights. The percentage of voting rights attributable to treasury shares is stated as 5.82 per cent.